source
- Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3Milestone Pharmaceuticals is cutting costs and staff following the FDA approval of its heart arrhythmia treatment, with two top executives departing the leadership team. The company said in its thi…Endpoints · 1h ago↗ source
- Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filingPlus, news about Merck KGaA, Rezolute, Vir, Orakl and Cellectis. Regeneron’s mid-stage POTS data: The biotech’s monoclonal antibody, baloncibart, given at 450 mg led to an average 11.4-beat-per-min…Endpoints · 1h ago↗ source
- American Cancer Society updates prostate cancer screening guidanceFor the first time in 16 years the American Cancer Society (ACS) has updated its guideline for prostate cancer screening as it drives to boost detection of the disease before it spreads.